

1. showing statistical significance in all of them

- 2. showing statistical significance in some of them with "supportive evidence" in the others
- 3. showing statistical significance in some of them with no "detrimental" effect in the remaining
- 4. showing "therapeutic equivalence" in all of them
- 5. forming groups of the primary variables and showing statistical significance in all variables for at least one group
- 6. defining a "response" criterion which involves all the primary variables and showing statistical significance and clinical relevance for the response variable
- 7. defining a composite and showing statistical significance for the composite

Common to all is the "1-sidedness" of the winning scenarios


Examples for


1. showing statistical significance in all of them


- Alzheimer's Disease
 - ADAS-Cog
 - CIBIC+


• Migraine


- Pain-free at 2 hours
- Nausea at 2 hours
- Photosensitivity at 2 hours
- Phonosensitivity at 2 hours














example Insomnia

Primary variables

Look for benefit in onset of sleep.

Look for benefit in longer, continuous sleep.


• Effect on either variable would be important if the benefit in one variable is not achieved at the cost in the other.


example Pain


- The CHMP Points to Consider document on the treatment of Irritable Bowel Disease (2003)
 - requires to use measurements on abdominal discomfort/pain as one of two primary endpoints in placebo controlled trials and
 - recommends to pre-specify methods for adjusting for the use of rescue medication (established painkiller) which should be offered if needed for ethical reasons.

example Pain

- Use of painkiller medication is, however, an outcome variable
- Therefore, the effect of drug A in reducing discomfort/pain could also be observed indirectly as a reduction of the amount of rescue medication used.
 - If so, a reduced need for rescue medication intake should not be explainable by an increase in pain.
 - Also, reduced pain should not be achieved through increased intake of rescue medication.









step 3


- We note that a closed testing procedure that may reject some of the composite intersection null hypotheses but which does not reach down to the single variables will not considered sufficient for a positive judgement of the trial.
- We only consider a clinical trial successful if the closed testing procedure reaches down to the individual variables and for at least one of them the respective null hypothesis (e.g. of inferiority) is successfully rejected.


Literature review regarding directional considerations on multiple endpoints – early papers

- Perlman, M.D. (1969). One-sided testing problems in multivariate analysis. Annals of Mathematical Statistics 40, 549-567
- Tang, D.-I., Gnecco, C. Geller, N. (1989). An approximate likelihood ratio test for the normal mean vector with nonnegative components with application to clinical trials. *Biometrika* 76, 577
- Follmann, D. (1995). Multivariate tests for multiple endpoints in clinical trials. Statistics in Medicine 14, 1163-1175
- Follmann, D. (1996). A simple multivariate test for one-sided alternatives. Journal of the American Statistical Association 91, 854-861
- Wang, S.-J.(1998). A closed procedure based on Follmann's test for the analysis of multiple endpoints. *Communications in Statistics Theory and Methods* 27, 2461-2480.
- Bloch, D.A., Lai, T.L., Tubert-Bitter, P. (2001) One-sided tests in clinical trials with multiple endpoints. *Biometrics* 57, 1039-1047
- Tamhane, A.C. and Logan, B.R. (2002) Accurate critical constants for the onesided approximate likelihood ratio test for a normal mean vector when the covariance matrix is estimated. *Biometrics* 58, 650-656










The monotonicity requirement


if the data allow rejection of a null hypothesis $H_0: \begin{pmatrix} \mu_A - \mu_P \\ \nu_A - \nu_P \end{pmatrix} = \begin{pmatrix} 0 \\ 0 \end{pmatrix}$


the test must also reject $H_0^{\Delta} : \begin{pmatrix} \mu_A - \mu_P \\ \nu_A - \nu_P \end{pmatrix} = \begin{pmatrix} \varepsilon_1 \\ \eta_1 \end{pmatrix}$


for any $\Delta = (\varepsilon_1, \eta_1)$ with $\varepsilon \le \varepsilon_1 \le 0$, $\eta \le \eta_1 \le 0$.

Literature review regarding directional considerations on multiple endpoints - more recent articles - Sankoh, A.J., D'Agostino, R.B. and Huque, M.F. (2003). Efficacy endpoint selection and multiplicity adjustment methods in clinical trials with inherent multiple endpoint issues. Stat in Med 22, 3133-3150 - Perlman, M.D. and Wu, L. (2004). A note on one-sided tests with multiple endpoints. Biometrics 60, 276-280 - Tamhane, A.C. and Logan, B.R. (2004). A superiority-equivalence approach to one-sided tests on multiple endpoints in clinical trials. Biometrika 91, 715-727 - Röhmel J, Gerlinger C, Benda N, Läuter J.On Testing Simultaneously Non-inferiority in Two Multiple Primary Endpoints and Superiority in at Least One of Them. Biom Journal 48, 2006, 916-933 - Bloch, D.A., Lai, T.L., Su, Z. and Tubert-Bitter, P. A A combined superiority and non-inferiority approach to multiple endpoints in clinical trials. Stat in Med 26, 2007,1193-1207









What about satisfaction of the monotonoicity requirements?

- No problem with Bonferroni, Holm or Hochberg, because they are built on univariate p-values
- No problem with O'Brien because this is a linear combination of univariate statistics
- Problems with Follmann's test
- Potential problems with Läuter's procedure. A modification was necessary for ensuring the monotonicity requirement.
- Fortunately the necessary modifications will not come with additional costs except for situations that are normally not observed in real clinical trials..


O'Briens OLS and GLS applied for shifted null hypotheses $\Delta = (\Delta_x, \Delta_y)$ Test statistic: $t(\Delta_x, \Delta_y) = \sqrt{a} \frac{w_x(\bar{x}_A - \bar{x}_P - \Delta_x) + w_y(\bar{y}_A - \bar{y}_P - \Delta_y)}{\sqrt{w^T S w}}$ $a = \frac{n_A n_P}{n_A + n_P} \quad w_x = \frac{1}{\sqrt{s_{xx}}} \quad w_y = \frac{1}{\sqrt{s_{yy}}}$ For OLS: $w = \begin{pmatrix} w_x \\ w_y \end{pmatrix}$ For GLS $w = S^{-1} \begin{pmatrix} \sqrt{s_{xx}} \\ \sqrt{s_{yy}} \end{pmatrix}$ Note: for two variables OLS and GLS coincide


Läuter's method applied for shifted null hypotheses


$$\Delta = (\Delta_x, \Delta_y)$$
Test statistic: $t(\Delta_x, \Delta_y) = \sqrt{a} \frac{w_x(\bar{x}_A - \bar{x}_P - \Delta_x) + w_y(\bar{y}_A - \bar{y}_P - \Delta_y)}{\sqrt{w^T S w}}$


$$a = \frac{n_A n_P}{n_A + n_P} \quad w_x = \frac{1}{\sqrt{t_{xx}}} \quad w_y = \frac{1}{\sqrt{t_{yy}}} \quad w = \begin{pmatrix} w_x \\ w_y \end{pmatrix}$$


$$t_{xx} = \sum_{j=1}^{n_A} (x_{Aj} - \bar{x} - \frac{n_P}{n_A + n_P} \Delta_x)^2 + \sum_{j=1}^{n_P} (x_{Pj} - \bar{x} + \frac{n_A}{n_A + n_P} \Delta_x)^2$$

















Conclusions

- The original prompt for the research was the intention to find valid and powerful statistical procedures for demonstrating simultaneously non-inferiority in all multiple primary variables and superiority in at least one of them.
- The literature review was disappointing, because either noninferiority was not considered or the one-sided character of the problem was inadequately recognized or bootstrap procedures linked the non-inferiority tests with the superiority tests in a way that was suspicious to us.
- Besides the obvious idea to combine non-inferiority tests with a subsequent Holm's procedure we investigated the use of Läuter's method for this purpose.

